Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Galmed Pharmaceuticals ( (GLMD) ) is now available.
On April 9, 2026, Galmed Pharmaceuticals announced it has co-developed with Barcode Nanotech a new lipid nanoparticle-based, subcutaneously administered formulation of its SCD1 inhibitor Aramchol that can cross the blood–brain barrier and deliver the drug to the brain. In vitro data indicate Aramchol down-regulates α-synuclein aggregation without evident toxicity, positioning this brain-penetrant SCD1 inhibitor as a potentially disease-modifying therapy for Parkinson’s disease and other synucleinopathies and marking a strategic extension of Galmed’s lead asset from liver-focused uses into high-unmet-need CNS indications.
The collaboration leverages Barcode Nanotech’s AI-enabled in vivo screening platform to identify an optimal nanoparticle delivery vehicle capable of targeting the central nervous system. By reframing Aramchol as an attractive CNS therapeutic candidate at a time when no disease-modifying treatments exist for Parkinson’s disease, multiple system atrophy or dementia with Lewy bodies, Galmed potentially broadens its addressable market and enhances its strategic positioning in both neurology and advanced drug-delivery technologies.
The most recent analyst rating on (GLMD) stock is a Hold with a $0.56 price target. To see the full list of analyst forecasts on Galmed Pharmaceuticals stock, see the GLMD Stock Forecast page.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, recurring losses, and negative free cash flow with declining equity). Technicals also lean bearish with price below key moving averages and a negative MACD, while valuation remains difficult to support due to negative earnings and no indicated dividend yield.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing its SCD1 inhibitor Aramchol for liver, cardiometabolic and gastrointestinal oncological diseases, including NASH. The company is also seeking to expand and diversify its pipeline into additional cardiometabolic and innovative drug candidates aligned with its core expertise in drug development.
Average Trading Volume: 50,181
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.11M
For detailed information about GLMD stock, go to TipRanks’ Stock Analysis page.